Regeneron backs bluebird with $100 mn, jointly work on cancer therapies
Regeneron Pharmaceuticals Inc has announced to invest $100 million in cancer drug developer bluebird bio Inc, and jointly the companies will develop new cell therapies for cancer.
The investment will be at $238.10 per share, a premium of nearly 59 percent over bluebird's Friday closing price.
Bluebird bio's shares were up about 7 pct at $160.50 in premarket trading on Monday.
The companies will use Regeneron's VelociSuite platform technologies for the discovery of human antibodies as well as T cell receptors and bluebird's gene transfer techniques.
Bluebird's technology is more into the emerging class of treatments known as CAR-T therapy, which involves genetic manipulation of a patient's immune system.
The companies have selected six initial targets and will equally share the costs of research and development up to the point of submitting a marketing application in the United States.